Severe neurotoxicity due to 5-fluorouracil (FUra) has previously been described in a patient with familial pyrimidinemia. We now report the biochemical basis for both the pyrimidinemia and neurotoxicity in a patient we have recently studied. After administration of a "test" dose of FUra (25 mg/m2, 600 microCi[6-3H]FUra by intravenous bolus) to a patient who had previously developed neurotoxicity after FUra, a markedly prolonged elimination half-life (159 min) was observed with no evidence of FUra catabolites in plasma or cerebrospinal fluid and with 89.7% of the administered dose being excreted into the urine as unchanged FUra. Using a sensitive assay for dihydropyrimidine dehydrogenase in peripheral blood mononuclear cells, we demonstrated complete deficiency of enzyme activity in the patient and partial deficiency of enzyme activity in her father and children consistent with an autosomal recessive pattern of inheritance. Patients who are deficient in this enzyme are likely to develop severe toxicity after FUra administration.
R B Diasio, T L Beavers, J T Carpenter
Year: | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1969 | Total |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Citations: | 3 | 6 | 5 | 6 | 10 | 8 | 6 | 6 | 4 | 8 | 7 | 8 | 16 | 11 | 2 | 13 | 9 | 15 | 18 | 18 | 15 | 13 | 13 | 14 | 17 | 8 | 13 | 8 | 11 | 13 | 8 | 8 | 10 | 1 | 10 | 6 | 2 | 1 | 1 | 351 |
Title and authors | Publication | Year |
---|---|---|
Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial)
Hanrath MA, Banken E, van den Wildenberg SA, van de Kerkhof D, Moes DJ, Boisdron-Celle M, van den Bosch BJ, Bax R, Bet PM, Maring JG, Creemers GJ, van Hellemond IE, Deenen MJ |
Cancer Chemotherapy and Pharmacology | 2025 |
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice
Ho TT, Smith DM, Aquilante CL, Cicali EJ, El Rouby N, Hertz DL, Imanirad I, Patel JN, Scott SA, Swain SM, Tuteja S, Hicks JK |
Clinical Pharmacology and Therapeutics | 2025 |
Precision Treatment of Patients With GI Cancer Using Pre-emptive DPYD Genotyping/Phenotyping Plus Pharmacokinetic-Guided Dosing of 5-Fluorouracil
Fiebrich-Westra HB, Haroun C, van der Galiën R, den Besten-Bertholee D, Deenen MJ, Moes DJ, Bet PM, de Groot JW, Brohet RM, van Kuilenburg AB, Maring JG |
JCO Precision Oncology | 2025 |
Improving single nucleotide polymorphisms genotyping accuracy for dihydropyrimidine dehydrogenase testing in pharmacogenetics.
Montella A, Cantalupo S, D'Alterio G, Damiano V, Iolascon A, Capasso M |
2024 | |
DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review
Chan TH, Zhang JE, Pirmohamed M |
British Journal of Cancer | 2024 |
Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches
Lyrio RM, Rocha BR, Corrêa AL, Mascarenhas MG, Santos FL, Maia RD, Segundo LB, de Almeida PA, Moreira CM, Sassi RH |
Frontiers in Nephrology | 2024 |
Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
Cheng Y, Teng Z, Zhang Y, Jin B, Zheng Z, Man L, Wang Z, Teng Y, Yu P, Shi J, Luo Y, Wang Y, Zhang J, Zhang H, Liu J, Chen H, Xiao J, Zhao L, Zhang L, Jiang Y, Chen Y, Zhang J, Wang C, Liu S, Qu J, Qu X, Liu Y |
BMC Cancer | 2024 |
Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review
Cotan HT, Emilescu RA, Iaciu CI, Orlov-Slavu CM, Olaru MC, Popa AM, Jinga M, Nitipir C, Schreiner OD, Ciobanu RC |
Cancers | 2024 |
Characterization of Reference Materials for DPYD: A GeT-RM Collaborative Project
Gaedigk A, Turner AJ, Moyer AM, Zubiaur P, Boone EC, Wang WY, Broeckel U, Kalman LV |
The Journal of molecular diagnostics : JMD | 2024 |
Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients.
Callon S, Brugel M, Botsen D, Royer B, Slimano F, Feliu C, Gozalo C, Konecki C, Devie B, Carlier C, Daire V, Laurés N, Perrier M, Djerada Z, Bouché O |
Therapeutic advances in medical oncology | 2023 |
DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation.
Wigle TJ, Medwid S, Ross C, Schwarz UI, Kim RB |
Current oncology (Toronto, Ont.) | 2023 |
3D Printed Pharmaceutical Systems for Personalized Treatment in Metabolic Syndrome.
Alqahtani AA, Ahmed MM, Mohammed AA, Ahmad J |
Pharmaceutics | 2023 |
DPYD Testing: Time to Put Patient Safety First.
Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper TC, McLeod HL, O'Donnell PH, Relling MV, Rudek MA, Sissung TM, Smith DM, Sparreboom A, Swain SM, Walko CM |
Journal of Clinical Oncology | 2023 |
Evolution of predictive risk factor analysis for chemotherapy-related toxicity.
Hertz DL, Lustberg MB, Sonis S |
Supportive Care in Cancer | 2023 |
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing.
Glewis S, Alexander M, Khabib MNH, Brennan A, Lazarakis S, Martin J, Tie J, Lingaratnam S, Michael M |
British Journal of Cancer | 2022 |
Racial and ethnic differences in capecitabine toxicity in patients with gastrointestinal tract cancers.
Brazelton A, Yande S, Pope R, Johnson ML, Musher B, Trivedi MV |
Annals of Gastroenterology | 2022 |
Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy.
Diasio RB, Offer SM |
Cancers | 2022 |
Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis.
Laures N, Konecki C, Brugel M, Giffard AL, Abdelli N, Botsen D, Carlier C, Gozalo C, Feliu C, Slimano F, Djerada Z, Bouché O |
Pharmaceutics | 2022 |
Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door.
Donadio MDS, Carraro DM, Torrezan GT, de Mello CAL |
ecancermedicalscience | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays.
De Luca O, Salerno G, De Bernardini D, Torre MS, Simmaco M, Lionetto L, Gentile G, Borro M |
International journal of molecular sciences | 2022 |
A review of emerging and non-US FDA-approved topical agents for the treatment of basal cell carcinoma
N Kash, S Silapunt |
Future Oncology | 2021 |
Oncologic Emergency Medicine: Principles and Practice
KH Todd, CR Thomas, K Alagappan |
2021 | |
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)
K Heinrich, DP Modest, I Ricard, LF von Weikersthal, T Decker, F Kaiser, U Graeven, J Uhlig, M Schenk, J Freiberg-Richter, B Peuser, C Denzlinger, C Giessen-Jung, A Stahler, M Michl, S Held, A Jung, T Kirchner, S Stintzing, V Heinemann |
European Journal of Cancer | 2021 |
Pharmacogenomic‐Guided Therapy in Colorectal Cancer
RB Diasio, F Innocenti, SM Offer |
Clinical Pharmacology & Therapeutics | 2021 |
Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events
TJ Wigle, BL Povitz, S Medwid, WA Teft, RM Legan, J Lenehan, S Nevison, V Panuganty, D Keller, J Mailloux, V Siebring, S Sarma, Y Choi, S Welch, E Winquist, UI Schwarz, RB Kim |
Clinical and Translational Science | 2021 |
The Interaction of Porcine Dihydropyrimidine Dehydrogenase with the Chemotherapy Sensitizer: 5-Ethynyluracil
DC Forouzesh, BA Beaupre, A Butrin, Z Wawrzak, D Liu, GR Moran |
Biochemistry | 2021 |
Mammalian dihydropyrimidine dehydrogenase
DC Forouzesh, GR Moran |
Archives of Biochemistry and Biophysics | 2021 |
First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study
C Gallois, E Hafliger, E Auclin, A Perret, C Coutzac, A Turpin, A Pellat, V Randrian, D Basile, R Faroux, S Pernot, C Locher, V Hautefeuille, O Dubreuil, LJ Palmieri, M Dior, P Artru, J Taieb |
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2021 |
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
P García-Alfonso, M Saiz-Rodríguez, R Mondéjar, J Salazar, D Páez, AM Borobia, MJ Safont, I García-García, R Colomer, X García-González, MJ Herrero, LA López-Fernández, F Abad-Santos |
Clinical and Translational Oncology | 2021 |
Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy.
Ruiz-Bañobre J, Goel A |
Advances in cancer research | 2021 |
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients
N Matsumoto, Y Kubota, H Ishida, M Sekido, R Ohkuma, T Ishiguro, Y Hirasawa, H Ariizumi, T Tsunoda, T Ikusue, K Kobayashi, A Hisamatsu, H Toshima, K Shimada, K Fujita |
Cancer Chemotherapy and Pharmacology | 2020 |
All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide
F Innocenti, SC Mills, H Sanoff, J Ciccolini, HJ Lenz, G Milano |
2020 | |
Small intestinal mucosal injury and its risk factors in patients with gastrointestinal cancer who developed complicated fluoropyrimidine-induced diarrhea
M Sakumura, T Ando, A Hosokawa, T Nakajima, I Motoo, H Mihara, A Ueda, S Kajiura, S Nanjo, H Fujinami, K Ogawa, I Yasuda |
BMC Gastroenterology | 2020 |
Adjuvant Chemotherapy for Stage III Colon Cancer
J Taieb, C Gallois |
Cancers | 2020 |
Comparison of 4 Screening Methods for Detecting Fluoropyrimidine Toxicity Risk: Identification of the Most Effective, Cost-Efficient Method to Save Lives
O Capitain, V Seegers, JP Metges, R Faroux, C Stampfli, M Ferec, TM Budnik, H Senellart, V Rossi, N Blouin, J Dauvé, M Campone |
Dose-Response | 2020 |
Posterior reversible encephalopathy syndrome: A rare neurotoxicity after capecitabine
M Monti, D Barone, E Amadori, G Bartolini, S Ruscelli, GL Frassineti |
Journal of Oncology Pharmacy Practice | 2020 |
Toxic and Adverse Effects of Chemotherapy with 5-Fluoropyrimidine Drugs. Could Dihydropyrimidine Dehydrogenase Enzyme Screening Serve as a Prerequisite to Successful Chemotherapy?
VT Minchev |
2020 | |
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper
B Wörmann, C Bokemeyer, T Burmeister, CH Köhne, M Schwab, D Arnold, JU Blohmer, M Borner, S Brucker, I Cascorbi, T Decker, M de Wit, A Dietz, H Einsele, W Eisterer, G Folprecht, W Hilbe, J Hoffmann, W Knauf, V Kunzmann, CR Largiadèr, S Lorenzen, D Lüftner, M Moehler, MM Nöthen, C Pox, A Reinacher-Schick, A Scharl, B Schlegelberger, T Seufferlein, M Sinn, M Stroth, I Tamm, L Trümper, M Wilhelm, E Wöll, RD Hofheinz |
Oncology Research and Treatment | 2020 |
Extensive epigenetic and transcriptomic variability between genetically identical human B-lymphoblastoid cells with implications in pharmacogenomics research
L Ozgyin, A Horvath, Z Hevessy, BL Balint |
Scientific Reports | 2019 |
Hyperammonemia after capecitabine associated with occult impairment of the urea cycle
G Chu, J Salzman |
Cancer Medicine | 2019 |
DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
TJ Wigle, EV Tsvetkova, SA Welch, RB Kim |
Pharmaceutics | 2019 |
Basal Cell Carcinoma: Advances in Treatment and Research
MR Migden, L Chen, S Silapunt |
2019 | |
Fluoropyrimidine-Associated Cardiotoxicity
J Kanduri, LA More, A Godishala, A Asnani |
Cardiology Clinics | 2019 |
Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs
V Sharma, SK Gupta, M Verma |
Cancer Chemotherapy and Pharmacology | 2019 |
5-fluorouracil and cardiotoxicity: a review
JD Sara, J Kaur, R Khodadadi, M Rehman, R Lobo, S Chakrabarti, J Herrmann, A Lerman, A Grothey |
Therapeutic advances in medical oncology | 2018 |
SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand
R Palmirotta, C Carella, E Silvestris, M Cives, SL Stucci, M Tucci, D Lovero, F Silvestris |
Oncotarget | 2018 |
Colorectal Cancer - Diagnosis, Screening and Management
J Chen |
2018 | |
Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre
M Moloney, D Faulkner, E Link, D Rischin, B Solomon, AM Lim, JR Zalcberg, M Jefford, M Michael |
Cancer Chemotherapy and Pharmacology | 2018 |
A direct, sensitive and efficient method for determination of alpha-fluoro-beta-alanine in urine: Evaluating the influence of magnesium isoglycyrrhizinate on excretion in rat model
Z Wang, Y Yang, F Zhang, M Li, J Chen, H Man, W Jiang, R Zhang, S Gao, W Chen |
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences | 2018 |
Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer
SL Chan, AW Chan, F Mo, BB Ma, KC Wong, D Lam, FS Mok, AT Chan, T Mok, KC Chan |
The oncologist | 2018 |
Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo
L Patras, B Sylvester, L Luput, A Sesarman, E Licarete, A Porfire, D Muntean, DM Drotar, AD Rusu, AL Nagy, C Catoi, I Tomuta, L Vlase, M Banciu, M Achim |
Cancer biology & therapy | 2017 |
Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo
L Patras, B Sylvester, L Luput, A Sesarman, E Licarete, A Porfire, D Muntean, DM Drotar, AD Rusu, AL Nagy, C Catoi, I Tomuta, L Vlase, M Banciu, M Achim |
Cancer biology & therapy | 2017 |
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
U Amstutz, LM Henricks, SM Offer, J Barbarino, JH Schellens, JJ Swen, TE Klein, HL McLeod, KE Caudle, RB Diasio, M Schwab |
Clinical Pharmacology & Therapeutics | 2017 |
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach
M Boisdron-Celle, O Capitain, R Faroux, C Borg, JP Metges, MP Galais, M Kaassis, J Bennouna, K Bouhier-Leporrier, E Francois, I Baumgaertner, V Guerin-Meyer, O Cojocarasu, C Roemer-Becuwe, C Stampfli, L Rosenfeld, T Lecompte, V Berger, A Morel, E Gamelin |
Seminars in Oncology | 2017 |
Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases: Genetic variability and treatment response
A DHAWAN, M RUWALI, MC PANT, Q RAHMAN, D PARMAR |
Asia-Pacific Journal of Clinical Oncology | 2016 |
Improving Safety of Fluoropyrimidine Chemotherapy by Individualizing Treatment Based on Dihydropyrimidine Dehydrogenase Activity – Ready for Clinical Practice?
D Meulendijks, A Cats, JH Beijnen, JH Schellens |
Cancer Treatment Reviews | 2016 |
5-Fluorouracil sensitivity varies among oral micro-organisms
TV de Wiele, B Vanhoecke, E Vanlancker, R Smet, R Props |
Journal of Medical Microbiology | 2016 |
Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid
M Yan, C Ho, E Winquist, D Jonker, D Rayson, L Stitt, S Tokmakejian, A Tomiak, MD Vincent |
Clinical Colorectal Cancer | 2016 |
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs
D Bertholee, JG Maring, AB van Kuilenburg |
Clinical Pharmacokinetics | 2016 |
Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience
A Sahu, A Ramaswamy, V Ostwal |
Journal of Gastrointestinal Oncology | 2016 |
Inborn Metabolic Diseases
JM Saudubray, MR Baumgartner, J Walter |
Inborn Metabolic Diseases | 2016 |
Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population
T Elraiyah, CR Jerde, S Shrestha, R Wu, Q Nie, NH Giama, V Sarangi, LR Roberts, SM Offer, RB Diasio |
Clinical Pharmacology & Therapeutics | 2016 |
Pharmacogenetics of Cancer Drugs
DL Hertz, J Rae |
Annual Review of Medicine | 2015 |
Controlled delivery of hollow corn protein nanoparticles via non-toxic crosslinking: in vivo and drug loading study
H Xu, L Shen, L Xu, Y Yang |
Biomedical Microdevices | 2015 |
Genotype–phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction
G Gentile, A Botticelli, L Lionetto, F Mazzuca, M Simmaco, P Marchetti, M Borro |
The Pharmacogenomics Journal | 2015 |
Pharmacogenomics of fluorouracil-based chemotherapy toxicity
S Matsusaka, HJ Lenz |
Expert Opinion on Drug Metabolism & Toxicology | 2015 |
Principles of Translational Science in Medicine
AR van der Velde, WC Meijers, RA de Boer |
Principles of Translational Science in Medicine | 2015 |
Reviews in Cell Biology and Molecular Medicine
DL Hertz, HL McLeod |
Reviews in Cell Biology and Molecular Medicine | 2015 |
A systematic review on the importance of genotyping and phenotyping in fluoropyrimidine treatment
AL Deac, CC Burz, HF Bocșe, IC Bocșan, AD Buzoianu |
Medicine and pharmacy reports | 2015 |
'Toxgnostics': an unmet need in cancer medicine
D Church, R Kerr, E Domingo, D Rosmarin, C Palles, K Maskell, I Tomlinson, D Kerr |
Nature Reviews Cancer | 2014 |
Eniluracil Plus 5-Fluorouracil and Leucovorin: Treatment for Metastatic Breast Cancer Patients in Whom Capecitabine Treatment Rapidly Failed
E Rivera, JC Chang, V Semiglazov, O Burdaeva, MG Kirby, T Spector |
Clinical Breast Cancer | 2014 |
La dihydropyrimidine déshydrogénase (DPD)
E Gamelin, M Boisdron-Celle, A Morel |
Oncologie | 2014 |
Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer
T Ochiai, M Umeki, H Miyake, T Iida, M Okumura, K Ohno, M Sakamoto, N Miyoshi, M Takahashi, H Tsumura, Y Tokunaga, H Naitou, T Fukui |
Oncology reports | 2014 |
Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
LM Soveri, K Hermunen, A Gramont, T Poussa, E Quinaux, P Bono, T André, P Österlund |
European Journal of Cancer | 2014 |
DPYD Variants to Predict 5-FU Toxicity: The Ultimate Proof
F Innocenti |
JNCI Journal of the National Cancer Institute | 2014 |
Pharmacogenetic biomarkers for predicting drug response
PC Bank, JJ Swen, HJ Guchelaar |
Expert Review of Molecular Diagnostics | 2014 |
Guidance on the management of diarrhoea during cancer chemotherapy
J Andreyev, P Ross, C Donnellan, E Lennan, P Leonard, C Waters, L Wedlake, J Bridgewater, R Glynne-Jones, W Allum, I Chau, R Wilson, D Ferry |
The Lancet Oncology | 2014 |
Personalizing colon cancer therapeutics: targeting old and new mechanisms of action
CL Kline, WS El-Deiry |
Pharmaceuticals (Basel, Switzerland) | 2013 |
A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity
SM Offer, AM Lee, LK Mattison, C Fossum, NJ Wegner, RB Diasio |
Clinical Pharmacology & Therapeutics | 2013 |
Personalized Dosing via Pharmacokinetic Monitoring of 5-Fluorouracil Might Reduce Toxicity in Early- or Late-Stage Colorectal Cancer Patients Treated With Infusional 5-Fluorouracil-Based Chemotherapy Regimens
CL Kline, A Schiccitano, J Zhu, C Beachler, H Sheikh, HA Harvey, HB Mackley, K McKenna, K Staveley-O'Carroll, L Poritz, E Messaris, D Stewart, J Sivik, WS El-Deiry |
Clinical Colorectal Cancer | 2013 |
Emery and Rimoin's Principles and Practice of Medical Genetics
DC Wallace, MT Lott, V Procaccio |
Emery and Rimoin's Principles and Practice of Medical Genetics | 2013 |
Handbook of Therapeutic Biomarkers in Cancer
E Gross, A Kuilenburg |
Handbook of Therapeutic Biomarkers in Cancer | 2013 |
Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients
AB van Kuilenburg, JG Maring |
Pharmacogenomics | 2013 |
Pharmacogenetics in dermatology: a patient-centered update
NI Comfere, ON Ikediobi, MS Peters, RA el-Azhary, LE Gibson |
International Journal of Dermatology | 2013 |
Genetics of Population Differences in Drug Response
M Bachtiar, CG Lee |
Current Genetic Medicine Reports | 2013 |
Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
KE Caudle, CF Thorn, TE Klein, JJ Swen, HL McLeod, RB Diasio, M Schwab |
Clinical Pharmacology & Therapeutics | 2013 |
Detection of complete dihydropyrimidine dehydrogenase deficiency in a Tunisian family using a simple phenotypic test
A Mani, M Nouira, SB Ahmed, S Saguem |
Indian journal of pharmacology | 2013 |
Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in China
X Zhang, B Sun, Z Lu |
International journal of medical sciences | 2013 |
Dihydropyrimidine dehydrogenase and fluoropyrimidines: a review of current dose adaptation practices and the impact on the future of personalized medicine using 5-fluorouracil
M Boisdron-Celle, P Biason, E Gamelin, A Morel |
Colorectal Cancer | 2013 |
Indirect assessment of dihydropyrimidine dehydrogenase activity in cats: U:UH 2 in cats
CF Saba, CW Schmiedt, KG Freeman, GL Edwards |
Veterinary and Comparative Oncology | 2013 |
13C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients
GF Cunha-Junior, L Marco, L Bastos-Rodrigues, MB Bolina, FL Martins, GA Pianetti, IC Cesar, LG Coelho |
Cancer Chemotherapy and Pharmacology | 2013 |
Médecine personnalisée en cancérologie digestive
O Bouché, P Laurent-Puig |
2013 | |
Phenotypic Profiling of DPYD Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and In Vitro Measurement of Enzyme Activity
SM Offer, NJ Wegner, C Fossum, K Wang, RB Diasio |
Cancer research | 2013 |
A Rapid HPLC-ESI-MS/MS Method for Determination of Dihydrouracil/Uracil Ratio in Plasma: Evaluation of Toxicity to 5-Flurouracil in Patients With Gastrointestinal Cancer :
IC César, GF Cunha-Júnior, RM Byrro, LG Coelho, GA Pianetti |
Therapeutic Drug Monitoring | 2012 |
Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a c.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy :
AB van Kuilenburg, P Häusler, A Schalhorn, MW Tanck, JH Proost, C Terborg, D Behnke, W Schwabe, K Jabschinsky, JG Maring |
Clinical Pharmacokinetics | 2012 |
Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis
MB Garg, LF Lincz, K Adler, FE Scorgie, SP Ackland, JA Sakoff |
British Journal of Cancer | 2012 |
A nanogel of on-site tunable pH-response for efficient anticancer drug delivery
T Zhou, C Xiao, J Fan, S Chen, J Shen, W Wu, S Zhou |
Acta Biomaterialia | 2012 |
Accidental and experimentally induced 5-fluorouracil toxicity in dogs: 5-Fluorouracil toxicity in dogs
RS Sayre, JW Barr, EM Bailey |
Journal of Veterinary Emergency and Critical Care | 2012 |
Metabolomics
RW Millard, PR Rosevear |
Journal of the American College of Cardiology | 2012 |
Cancer chemotherapy: A critical analysis of its 60 years of history
D Galmarini, CM Galmarini, FC Galmarini |
Critical Reviews in Oncology/Hematology | 2012 |
Let’s get personal: predicting thiopurine and fluoropyrimidine toxicity
A Corrigan, M Arenas-Hernandez, P Blaker, J Sanderson, A Marinaki |
Personalized Medicine | 2012 |
Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy
AB Kuilenburg, P Häusler, A Schalhorn, MW Tanck, JH Proost, C Terborg, D Behnke, W Schwabe, K Jabschinsky, JG Maring |
Clinical Pharmacokinetics | 2012 |
Biomarkers in Oncology
HJ Lenz |
2012 | |
Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy
AB van Kuilenburg, P Häusler, A Schalhorn, MW Tanck, JH Proost, C Terborg, D Behnke, W Schwabe, K Jabschinsky, JG Maring |
Clinical Pharmacokinetics | 2012 |
Multi-functional core-shell hybrid nanogels for pH-dependent magnetic manipulation, fluorescent pH-sensing, and drug delivery
W Wu, J Shen, Z Gai, K Hong, P Banerjee, S Zhou |
Biomaterials | 2011 |
Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: A 5-year multicenter observational survey* :
GR Gristina, M Antonelli, G Conti, A Ciarlone, S Rogante, C Rossi, G Bertolini |
Critical Care Medicine | 2011 |
Burger's Medicinal Chemistry and Drug Discovery
S Bruno, L Ronda, S Faggiano, S Bettati, A Mozzarelli |
Burger's Medicinal Chemistry and Drug Discovery | 2010 |
Pharmaceutical Sciences Encyclopedia
D Farkas, RI Shader, LL von Moltke, DJ Greenblatt |
Pharmaceutical Sciences Encyclopedia | 2010 |
Cardiotoxicity of Non-Cardiovascular Drugs
FD Lisa, M Semenzato, A Carpi, S Menazza, N Kaludercic, R Menabò, M Canton |
Cardiotoxicity of Non-Cardiovascular Drugs | 2010 |
Selection of extreme phenotypes: the role of clinical observation in translational research
JL Pérez-Gracia, A Gúrpide, MG Ruiz-Ilundain, CA Alegría, R Colomer, J García-Foncillas, IM Bermejo |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2010 |
Insights into the mechanism of dihydropyrimidine dehydrogenase from site-directed mutagenesis targeting the active site loop and redox cofactor coordination
B Lohkamp, N Voevodskaya, Y Lindqvist, D Dobritzsch |
Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics | 2010 |
Breath biomarkers for personalized medicine
AS Modak |
Personalized Medicine | 2010 |
Clinical significance of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in oral squamous cell carcinoma
M Tsuzuki, T Satomi, H Chiba |
Oral Medicine & Pathology | 2010 |
Dihydropyrimidine Dehydrogenase Deficiency Caused by a Novel Genomic Deletion c.505_513del ofDPYD
AB van Kuilenburg, J Meijer, G Gökcay, T Baykal, ME Rubio-Gozalbo, AN Mul, CE de Die-Smulders, P Weber, AC Mori, J Bierau, B Fowler, K Macke, JO Sass, R Meinsma, JB Hennermann, P Miny, L Zoetekouw, J Roelofsen, R Vijzelaar, J Nicolai, RC Hennekam |
Nucleosides, Nucleotides and Nucleic Acids | 2010 |
Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study
A Tsunoda, K Nakao, M Watanabe, N Matsui, A Ooyama, M Kusano |
Annals of Oncology | 2010 |
Neurocatástrofes farmacológicas
CT García |
Neurología | 2010 |
The Value of Dihydrouracil/Uracil Plasma Ratios in Predicting 5-Fluorouracil-Related Toxicity in Colorectal Cancer Patients
MH Kristensen, P Pedersen, J Mejer |
J INT MED RES | 2010 |
Variants in the Dihydropyrimidine Dehydrogenase, Methylenetetrahydrofolate Reductase and Thymidylate Synthase Genes Predict Early Toxicity of 5-Fluorouracil in Colorectal Cancer Patients
MH Kristensen, PL Pedersen, GV Melsen, J Ellehauge, J Mejer |
J INT MED RES | 2010 |
Pharmacogenetics: Making cancer treatment safer and more effective
WG Newman |
2010 | |
Identification of genes conferring resistance to 5-fluorouracil
BK Yoo, R Gredler, N Vozhilla, Z Su, D Chen, T Forcier, K Shah, U Saxena, U Hansen, PB Fisher, D Sarkar |
Proceedings of the National Academy of Sciences | 2009 |
Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy
T Sakaeda, M Yamamori, A Kuwahara, K Nishiguchi |
Advanced Drug Delivery Reviews | 2009 |
Clinically available pharmacogenomics tests
DA Flockhart, T Skaar, DS Berlin, TE Klein, AT Nguyen |
Clinical Pharmacology & Therapeutics | 2009 |
Pharmacogenetics and pharmacogenomics of anticancer agents
RS Huang, MJ Ratain |
CA: a cancer journal for clinicians | 2009 |
13C-5-FU breath test current status and future directions: a comprehensive review
HH Ezzeldin, EP Acosta, LK Mattison, J Fourie, A Modak, RB Diasio |
Journal of Breath Research | 2009 |
Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment
S Shimoyama |
Journal of Gastroenterology and Hepatology | 2009 |
Pharmacogenetics: implementing personalized medicine
E Mini, S Nobili |
Clinical Cases in Mineral and Bone Metabolism | 2009 |
Pharmacology and Therapeutics
BL Clarke, S Khosla |
Pharmacology & Therapeutics | 2009 |
Toxicity and Efficacy of 5-Fluorouracil and Capecitabine in a Patient With TYMS Gene Polymorphism: A Challenge or a Dilemma?
A Shahrokni, MR Rajebi, MW Saif |
Clinical Colorectal Cancer | 2009 |
Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics
HK Sanoff, HL McLeod |
Seminars in colon & rectal surgery | 2008 |
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1
K Fujita, W Yamamoto, S Endo, H Endo, F Nagashima, W Ichikawa, R Tanaka, T Miya, K Araki, K Kodama, Y Sunakawa, M Narabayashi, K Miwa, Y Ando, Y Akiyama, K Kawara, T Kamataki, Y Sasaki |
Cancer Science | 2008 |
Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer
B Vincenzi, G Schiavon, F Pantano, D Santini, G Tonini |
Nature Clinical Practice Oncology | 2008 |
Cerebellar Toxicity with Capecitabine in a Patient with Metastatic Breast Cancer
M Mukesh, P Murray |
Clinical Oncology | 2008 |
Correlation between Clinical Pathologic Factors and Activity of 5-FU-Metabolizing Enzymes in Colorectal Cancer
T Yamada, N Tanaka, K Yokoi, T Seya, Y Kanazawa, M Koizumi, Y Ohaki, T Tajiri |
Journal of Nippon Medical School | 2008 |
Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene
AB van Kuilenburg, JG Maring, A Schalhorn, C Terborg, H Schmalenberg, D Behnke, W Schwabe, K Jabschinsky, P Hausler |
Nucleosides, Nucleotides and Nucleic Acids | 2008 |
Identification of Two Novel Mutations C79X and R235Q in the Dihydropyrimidine Dehydrogenase Gene in a Patient Presenting With Hematuria
AB van Kuilenburg, J Meijer, D Dobritzsch, B Lohkamp, W Ruitenbeek, J Roelofsen, NG Abeling, M Duran, C Buzing |
Nucleosides, Nucleotides and Nucleic Acids | 2008 |
Altered Dihydropyrimidine Dehydrogenase Activity Associated with Mild Toxicity in Patients Treated with 5-Fluorouracil Containing Chemotherapy
AB van Kuilenburg, HJ Klumpen, AM Westermann, L Zoetekouw, PJ Bakker, HJ Guchelaar, DJ Richel |
Nucleosides, Nucleotides and Nucleic Acids | 2008 |
Molecular Epidemiology: Applications in Cancer and Other Human Diseases
J Barnholtz-Sloan, I Halder, M Shriver |
Molecular Epidemiology: Applications in Cancer and Other Human Diseases | 2008 |
Surface-enhanced Raman Spectral Measurements of 5-Fluorouracil in Saliva
S Farquharson, A Gift, C Shende, F Inscore, B Ordway, C Farquharson, J Murren |
Molecules (Basel, Switzerland) | 2008 |
Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group
M Schwab, UM Zanger, C Marx, E Schaeffeler, K Klein, J Dippon, R Kerb, J Blievernicht, J Fischer, U Hofmann, C Bokemeyer, M Eichelbaum |
Journal of Clinical Oncology | 2008 |
Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer
E Gamelin, R Delva, J Jacob, Y Merrouche, JL Raoul, D Pezet, E Dorval, G Piot, A Morel, M Boisdron-Celle |
Journal of Clinical Oncology | 2008 |
Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response
F Innocenti |
2008 | |
HPLC with UV or Mass Spectrometric Detection for Quantifying Endogenous Uracil and Dihydrouracil in Human Plasma
R Švobaitė, I Solassol, F Pinguet, L Ivanauskas, J Brès, FM Bressolle |
Clinical chemistry | 2008 |
CYP2A6 and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1
Fujita K, Yamamoto W, Endo S, Endo H, Nagashima F, Ichikawa W, Tanaka R, Miya T, Araki K, Kodama K, Sunakawa Y, Narabayashi M, Miwa K, Ando Y, Akiyama Y, Kawara K, Kamataki T, Sasaki Y |
Cancer Science | 2008 |
Targeted Therapies in Cancer
M Dietel |
2007 | |
Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study
AA Garcia, JA Blessing, KM Darcy, HJ Lenz, W Zhang, E Hannigan, DH Moore |
Gynecologic Oncology | 2007 |
Clinical, biochemical and genetic findings in two siblings with a dihydropyrimidinase deficiency
AB van Kuilenburg, J Meijer, D Dobritzsch, R Meinsma, M Duran, B Lohkamp, L Zoetekouw, NG Abeling, HL van Tinteren, AM Bosch |
Molecular Genetics and Metabolism | 2007 |
Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin
AB van Kuilenburg, HJ Klumpen, AM Westermann, L Zoetekouw, HV Lenthe, PJ Bakker, DJ Richel, HJ Guchelaar |
European Journal of Cancer | 2007 |
Thymidylate Synthase (TYMS) and Dihydropyrimidine Dehydrogenase (DPYD) Polymorphisms in the Korean Population for Prediction of 5-Fluorouracil-Associated Toxicity
HJ Cho, YS Park, WK Kang, JW Kim, SY Lee |
Therapeutic Drug Monitoring | 2007 |
SSCP Screening of the Dihydropyrimidine Dehydrogenase Gene Polymorphisms of the Japanese Population Using a Semi-automated Electrophoresis Unit
Y Okamoto, A Ueta, S Sumi, T Ito, Y Okubo, Y Jose, A Ninomiya, H Togari, M Nishida |
Biochemical Genetics | 2007 |
Dépistage des patients déficitaires en dihydropyrimidine déhydrogénase avant traitement par fluoropyrimidines
E Gamelin, M Boisdron-Celle, A Morel |
Thérapie | 2007 |
Pour ou contre le phénotypage/génotypage des patients traités par le 5-fluorouracile pour prévenir les effets indésirables ?
R Coriat, S Chaussade |
Thérapie | 2007 |
Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area
SA Kaestner, GJ Sewell |
Clinical Oncology | 2007 |
5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency
M Boisdron-Celle, G Remaud, S Traore, AL Poirier, L Gamelin, A Morel, E Gamelin |
Cancer Letters | 2007 |
Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs
J Pander, H Gelderblom, HJ Guchelaar |
Expert Opinion on Pharmacotherapy | 2007 |
Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007
JB (Moderator), MF (Moderator), JH Beumer, E Chu, A Paolo, C Eng, M Extermann, E Gamelin, H Hurwitz, G Milano, SJ Salamone, L Shaw |
Clinical Colorectal Cancer | 2007 |
Toxicity Profile and Efficacy of Oral Capecitabine as Adjuvant Chemotherapy for Chinese Patients with Stage III Colon Cancer
CC Law, YT Fu, KK Chau, TS Choy, PF So, KH Wong |
Diseases of the Colon & Rectum | 2007 |
Pharmacogénétique des anticancéreux
E Gamelin, M Boisdron-Celle, A Morel, O Capitain |
Annales Pharmaceutiques Françaises | 2007 |
Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma
A Morel, M Boisdron-Celle, L Fey, P Lainé-Cessac, E Gamelin |
Clinical Biochemistry | 2007 |
Side Effects of Drugs Annual
T Vial, J Descotes, F Braun, M Behrend |
Side Effects of Drugs Annual | 2007 |
In Vivo Imaging of Cancer Therapy
AF Shields, P Price |
2007 | |
Ancestry and pharmacogenetics of antileukemic drug toxicity
S Kishi, C Cheng, D French, D Pei, S Das, EH Cook, N Hijiya, C Rizzari, GL Rosner, T Frudakis, CH Pui, WE Evans, MV Relling |
Blood | 2007 |
Pharmacogenetics of cancer chemotherapy
J Abraham, HM Earl, PD Pharoah, C Caldas |
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer | 2006 |
Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy
AV Boddy |
British Journal of Clinical Pharmacology | 2006 |
Pharmacogenetics in the Management of Breast Cancer – Prospects for Individualised Treatment
FH Blackhall, S Howell, B Newman |
Familial Cancer | 2006 |
Dihydropyrimidindehydrogenase-Mangel und Fluorpyrimidin-Toxizität / Dihydropyrimidine dehydrogenase deficiency and fluoropyrimidine toxicity
M Steiner |
LaboratoriumsMedizin | 2006 |
Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines
K Miyazaki, T Shibahara, D Sato, K Uchida, H Suzuki, H Matsui, A Yanaka, A Nakahara, Y Matsuzaki |
Journal of Gastroenterology | 2006 |
Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy
T Ochiai, K Nishimura, H Noguchi, M Kitajima, A Tsukada, E Watanabe, I Nagaoka, S Futagawa |
International Journal of Cancer | 2006 |
How may Anticancer Chemotherapy with Fluorouracil be Individualised?
S Ploylearmsaeng, U Fuhr, A Jetter |
Clinical Pharmacokinetics | 2006 |
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
ML Maitland, K Vasisht, MJ Ratain |
Trends in Pharmacological Sciences | 2006 |
Dihydropyrimidine dehydrogenase deficiency in an Indian population
MW Saif, L Mattison, T Carollo, H Ezzeldin, RB Diasio |
Cancer Chemotherapy and Pharmacology | 2006 |
Unpredicted Severe Toxicity after 5-Fluorouracil Treatment due to Dihydropyrimidine Dehydrogenase Deficiency
JH Baek, JG Kim, SN Kim, DH Kim, SK Sohn, YJ Hong, KB Lee |
The Korean Journal of Internal Medicine | 2006 |
Profiling Dihydropyrimidine Dehydrogenase Deficiency in Patients with Cancer Undergoing 5-Fluorouracil/Capecitabine Therapy
C Mercier, J Ciccolini |
Clinical Colorectal Cancer | 2006 |
Capecitabine-Induced Cerebellar Toxicity
D Renouf, S Gill |
Clinical Colorectal Cancer | 2006 |
Hand-Foot Syndrome Variant in a Dihydropyrimidine Dehydrogenase–Deficient Patient Treated with Capecitabine
MW Saif, A Elfiky, R Diasio |
Clinical Colorectal Cancer | 2006 |
Colorectal Cancer
G Chong, D Cunningham |
Colorectal Cancer | 2006 |
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
SJ Gardiner, EJ Begg |
Pharmacological reviews | 2006 |
The impact of genomics and proteomics in the clinic: functional genetic polymorphisms and their value in response and toxicity prediction in solid tumours
J Stoehlmacher |
Annals of Oncology | 2006 |
How may Anticancer Chemotherapy with Fluorouracil be Individualised?:
S Ploylearmsaeng, U Fuhr, A Jetter |
Clinical Pharmacokinetics | 2006 |
Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer:
TM Bosch, I Meijerman, JH Beijnen, JH Schellens |
Clinical Pharmacokinetics | 2006 |
Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics
R Soong, RB Diasio |
Pharmacogenomics | 2005 |
Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications
T Dervieux, B Meshkin, B Neri |
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis | 2005 |
Side effects during chemotherapy predict tumour response in advanced colorectal cancer
B Schuell, T Gruenberger, GV Kornek, N Dworan, D Depisch, F Lang, B Schneeweiss, W Scheithauer |
British Journal of Cancer | 2005 |
Does cisplatin (CDDP) function as a modulator of 5-fluorouracil (5-FU) antitumor action? A study based on a clinical trial
S Matsusaka, T Nagareda, H Yamasaki |
Cancer Chemotherapy and Pharmacology | 2005 |
Analysis of 5-fluorouracil in saliva using surface-enhanced Raman spectroscopy
S Farquharson, C Shende, FE Inscore, P Maksymiuk, A Gift |
Journal of Raman Spectroscopy | 2005 |
Genetic factors influencing Pyrimidine-antagonist chemotherapy
JG Maring, HJ Groen, FM Wachters, DR Uges, EG de Vries |
The Pharmacogenomics Journal | 2005 |
Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function
AB van Kuilenburg, R Meinsma, E Beke, B Bobba, P Boffi, GM Enns, DR Witt, D Dobritzsch |
Biological Chemistry | 2005 |
Individualized chemotherapy based on genetic and genomic profiling
S Iqbal, HJ Lenz |
Current Colorectal Cancer Reports | 2005 |
Pharmacogenetics for individualized cancer chemotherapy
T Efferth, M Volm |
Pharmacology & Therapeutics | 2005 |
Detection of 5-fluorouracil in saliva using surface-enhanced Raman spectroscopy
S Farquharson, AD Gift, C Shende, P Maksymiuk, FE Inscore, J Murran |
Vibrational Spectroscopy | 2005 |
5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice
F Innocenti, R Danesi, G Bocci, G Natale, MD Tacca |
Toxicology and Applied Pharmacology | 2005 |
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6–12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study
AA Garcia, JA Blessing, HJ Lenz, KM Darcy, RS Mannel, DS Miller, N Husseinzadeh |
Gynecologic Oncology | 2005 |
Sequence Analysis of the 5′-Flanking Regions of Human Dihydropyrimidine Dehydrogenase Gene: Identification of a New Polymorphism Related with Effects of 5-Fluorouracil
T Hasegawa, H Kim, M Fukushima, Y Wataya |
Nucleosides, Nucleotides and Nucleic Acids | 2005 |
Dihydropyrimidine déshydrogénase (DPD) : rythme et conséquences
MA Barrat-Petit, C Naulin-Ifi, P Mahler, G Milano |
Pathologie Biologie | 2005 |
Pharmacogénétique des médicaments anticancéreux
L Chaisemartin, MA Loriot |
Pathologie Biologie | 2005 |
NEUROTOXIC EFFECTS OF .ALPHA.-FLUORO-.BETA.-ALANINE (FBAL) AND FLUOROACETIC ACID (FA) ON DOGS
K YAMASHITA, H YADA |
The Journal of Toxicological Sciences | 2004 |
Thymidylate Synthase Expression in Normal Colonic Mucosa: A Predictive Marker of Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-Based Adjuvant Chemotherapy
D Santini, B Vincenzi, G Perrone, C Rabitti, D Borzomati, M Caricato, AL Cesa, C Grilli, A Verzì, R Coppola, G Tonini |
Oncology | 2004 |
Using germ-line genetic variation to investigate and treat cancer
SA Savage, SJ Chanock |
Drug Discovery Today | 2004 |
Pyrimidine Degradation Defects and Severe 5‐Fluorouracil Toxicity
AB van Kuilenburg, R Meinsma, AH van Gennip |
Nucleosides Nucleotides & Nucleic Acids | 2004 |
CORRELATION BETWEEN CLINICAL PATHOPHYSIOLOGIC FEATURES AND EXPRESSION OF DIHYDROPYRIMIDINE DEHYDROGENASE (DPD), THYMIDYLATE SYNTHASE (TS), AND OROTATE PHOSPHORIBOSYL TRANSFERASE (OPRT) IN HEAD AND NECK CANCER
T ITO, S KOIKE, H KOSHU, T NASU, Y ABE, H INAMURA, M AOYAGI |
Toukeibu Gan | 2004 |
Primer on Medical Genomics: Part XII: Pharmacogenomics—General Principles With Cancer as a Model
MP Goetz, MM Ames, RM Weinshilboum |
Mayo Clinic Proceedings | 2004 |
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil
AB van Kuilenburg |
European Journal of Cancer | 2004 |
Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms and Their Association with 5-Fluorouracil/Leucovorin Chemotherapy in Colorectal Cancer
AX Zhu, TA Puchalski, VP Stanton, DP Ryan, JW Clark, S Nesbitt, O Charlat, P Kelly, E Kreconus, BA Chabner, JG Supko |
Clinical Colorectal Cancer | 2004 |
Dihydropyrimidine Dehydrogenase Deficiency, a Pharmacogenetic Syndrome Associated with Potentially Life-Threatening Toxicity Following 5-Fluorouracil Administration
H Ezzeldin, R Diasio |
Clinical Colorectal Cancer | 2004 |
Tailored Chemotherapy for Colorectal Cancer: A New Approach to Therapy
S Iqbal, J Stoehlmacher, HJ Lenz |
Cancer Investigation | 2004 |
Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
TA Rich, RC Shepard, ST Mosley |
Journal of Clinical Oncology | 2004 |
Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
WD Figg, HL McLeod |
2004 | |
Rapid Identification of Dihydropyrimidine Dehydrogenase Deficiency by Using a Novel 2- 13 C-Uracil Breath Test
LK Mattison, H Ezzeldin, M Carpenter, A Modak, MR Johnson, RB Diasio |
Clinical cancer research | 2004 |
Pharmacogenomics: marshalling the human genome to individualise drug therapy
WE Evans |
Gut | 2003 |
Molecular predictors of treatment and outcome in colorectal cancer
S Iqbal, HJ Lenz |
Current Gastroenterology Reports | 2003 |
Cancer pharmacogenomics: current and future applications
JW Watters, HL McLeod |
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer | 2003 |
Targeted therapy and pharmacogenomic programs
S Iqbal, HJ Lenz |
Cancer | 2003 |
Pharmacogenetic aspects in treatment of colorectal cancer – an update
J Stoehlmacher, E Goekkurt, HJ Lenz |
Pharmacogenomics | 2003 |
Inheritance and Drug Response
AE Guttmacher, FS Collins, R Weinshilboum |
New England Journal of Medicine | 2003 |
Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma
Y Mizutani, H Wada, O Yoshida, M Fukushima, H Nakanishi, M Nakao, T Miki |
European Journal of Cancer | 2003 |
Quantitation of dihydropyrimidine dehydrogenase (DPD) mRNA expression levels in normal colon and colorectal cancer tumor paraffin-embedded tissue specimens:
JY Liu, W Zhou, AD Sferruzza, RA Bender |
Anti-Cancer Drugs | 2003 |
Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil
NC Tebbutt, AR Norman, D Cunningham, M Allen, I Chau, J Oates, M Hill |
British Journal of Cancer | 2003 |
Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889
M Endo, M Miwa, H Eda, M Ura, H Tanimura, T Ishikawa, T Miyazaki-Nose, K Hattori, N Shimma, H Yamada-Okabe, H Ishitsuka |
International Journal of Cancer | 2003 |
Intratumoural Thymidylate Synthase and Dihydropyrimidine Dehydrogenase Activities are Good Predictors of 5-Fluorouracil Sensitivity in Colorectal Cancer
Y Ishibiki, M Kitajima, K Sakamoto, Y Tomiki, S Sakamoto, T Kamano |
J INT MED RES | 2003 |
Implications of Genetic Testing in the Management of Colorectal Cancer:
J Stoehlmacher, HJ Lenz |
American Journal of PharmacoGenomics | 2003 |
Chemotherapy individualization
Gareth J Veal, Sally A Coulthard, Alan V Boddy |
Investigational New Drugs | 2003 |
Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene
JG Maring, AB van Kuilenburg, J Haasjes, H Piersma, HJ Groen, DR Uges, AH van Gennip, EG de Vries |
British Journal of Cancer | 2002 |
Candidate gene approach for pharmacogenetic studies
HZ Ring, DL Kroetz |
Pharmacogenomics | 2002 |
Diagnosis and monitoring of inborn errors of metabolism using urease-pretreatment of urine, isotope dilution, and gas chromatography–mass spectrometry
T Kuhara |
Journal of Chromatography B | 2002 |
Screening and diagnosis of ?-ureidopropionase deficiency by gas chromatographic/mass spectrometric analysis of urine
M Ohse, M Matsuo, A Ishida, T Kuhara |
Journal of Mass Spectrometry | 2002 |
Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics
LK Mattison, R Soong, RB Diasio |
Pharmacogenomics | 2002 |
The impact of pharmacogenomics on gastrointestinal cancer therapy
T Seufferlein, BO Boehm |
Pharmacogenomics | 2002 |
The Effect of Dihydropyrimidine Dehydrogenase Deficiency on Outcomes with Fluorouracil
SJ Gardiner, EJ Begg, BA Robinson |
Adverse Drug Reactions and Toxicological Reviews | 2002 |
Dosing strategies for anticancer drugs: the good, the bad and body-surface area
A Felici, J Verweij, A Sparreboom |
European Journal of Cancer | 2002 |
Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil
Y Mizutani, H Nakanishi, O Yoshida, M Fukushima, B Bonavida, T Miki |
European Journal of Cancer | 2002 |
Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas
J Guillot |
Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas | 2002 |
The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research
JL Perez-Gracia, MG Ruiz-Ilundain, I Garcia-Ribas, EM Carrasco |
Cancer | 2002 |
Crystal Structure of the Productive Ternary Complex of Dihydropyrimidine Dehydrogenase with NADPH and 5-Iodouracil: IMPLICATIONS FOR MECHANISM OF INHIBITION AND ELECTRON TRANSFER
D Dobritzsch, S Ricagno, G Schneider, KD Schnackerz, Y Lindqvist |
The Journal of biological chemistry | 2002 |
Clinically Relevant Resistance in Cancer Chemotherapy
B Andersson, D Murray |
2002 | |
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy
Sherry Morgan-Meadows, James P Thomas, Daniel Mulkerin, Jordan D Berlin, Howard Bailey, Kim Binger, Jennifer Volkman, Dona Alberti, Chris Feierabend, Rebecca Marrocha, Rhoda Z Arzoomanian, George Wilding |
Investigational New Drugs | 2002 |
Determinants of prognosis and response to therapy in colorectal cancer
S Iqbal, HJ Lenz |
Current Oncology Reports | 2001 |
The clinical pharmacology of the oral fluoropyrimidines
CH Takimoto |
Current Problems in Cancer | 2001 |
PHARMACOGENOMICS: The Inherited Basis for Interindividual Differences in Drug Response
WE Evans, JA Johnson |
Annual Review of Genomics and Human Genetics | 2001 |
Cognitive Function and Reproductive Hormones in Adjuvant Therapy for Breast Cancer
CM Bender, KK Paraska, SM Sereika, CM Ryan, SL Berga |
Journal of Pain and Symptom Management | 2001 |
The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer
Y Mizutani, H Wada, M Fukushima, O Yoshida, O Ukimura, A Kawauchi, T Miki |
European Journal of Cancer | 2001 |
Simple gas chromatographic–mass spectrometric procedure for diagnosing pyrimidine degradation defects for prevention of severe anticancer side effects
T Kuhara, C Ohdoi, M Ohse |
Journal of Chromatography B: Biomedical Sciences and Applications | 2001 |
High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity
R Déporte-Féty, M Picot, M Amiand, A Moreau, L Campion, D Lanoë, N Renée, G Milano |
Journal of Chromatography B Biomedical Sciences and Applications | 2001 |
Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil
MR Johnson, RB Diasio |
Advances in Enzyme Regulation | 2001 |
Pharmacogenetics and cancer therapy
MV Relling, T Dervieux |
Nature Reviews Cancer | 2001 |
Fluorouracil and the New Oral Fluorinated Pyrimidines
JG Kuhn |
The Annals of pharmacotherapy | 2001 |
Phase I Clinical and Pharmacogenetic Trial of Irinotecan and Raltitrexed Administered Every 21 Days to Patients With Cancer
JP Stevenson, M Redlinger, LA Kluijtmans, W Sun, K Algazy, B Giantonio, DG Haller, C Hardy, AS Whitehead, PJ ODwyer |
Journal of Clinical Oncology | 2001 |
Surgery
JA Norton, RR Bollinger, AE Chang, SF Lowry, SJ Mulvihill, HI Pass, RW Thompson |
Surgery | 2001 |
Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells
N Takebe, SC Zhao, AU Ural, MR Johnson, D Banerjee, RB Diasio, JR Bertino |
Cancer Gene Therapy | 2001 |
Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouraeil and folinic acid
A Wein, C Riedel, F Köckerling, P Martus, U Baum, WM Brueckl, T Reck, R Ott, J Hänsler, T Bernatik, D Becker, T Schneider, W Hohenberger, EG Hahn |
Annals of Oncology | 2001 |
Colorectal Cancer: A Clinical Guide to Therapy
H Bleiberg, N Kemeny, P Rougier, H Wilke |
2001 | |
The oral fluorinated pyrimidines
J S de Bono, C J Twelves |
Investigational New Drugs | 2001 |
High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.
Habara K, Ajiki T, Kamigaki T, Nakamura T, Kuroda Y |
Japanese journal of cancer research : Gann | 2001 |
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group
A Ohtsu, H Baba, Y Sakata, Y Mitachi, N Horikoshi, K Sugimachi, T Taguchi |
British Journal of Cancer | 2000 |
Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase
HL Kindler, RL Schilsky |
Expert Opinion on Investigational Drugs | 2000 |
Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action
A Saleem, J Yap, S Osman, F Brady, SV Lucas, T Jones, PM Price, EO Aboagye |
The Lancet | 2000 |
In-vivo Drug Delivery of 5-Fluorouracil using Poly(2-hydroxyethyl methacrylate-co-acrylamide) Hydrogels
MD Blanco, O GARCIA, C GOMEZ, RL Sastre, JM Teijon |
Journal of Pharmacy and Pharmacology | 2000 |
Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator Eniluracil
SD Baker, RB Diasio, S OReilly, VS Lucas, SP Khor, SE Sartorius, RC Donehower, LB Grochow, T Spector, JA Hohneker, EK Rowinsky |
Journal of Clinical Oncology | 2000 |
Monogen bedingte Erbkrankheiten 1
D Ganten, K Ruckpaul |
2000 | |
Pharmacogenetics: A Tool for Individualising Antineoplastic Therapy
F Innocenti, L Iyer, MJ Ratain |
Clinical Pharmacokinetics | 2000 |
Pharmacology of fluorinated pyrimidines: eniluracil
S D Baker |
Investigational New Drugs | 2000 |
Therapeutic drug monitoring of antimetabolic cytotoxic drugs
L Lennard |
British Journal of Clinical Pharmacology | 1999 |
5-Fluorouracil toxicity
BJ Kennedy |
Cancer | 1999 |
Dihydropyrimidine Dehydrogenase Activity in a Korean Population
DR Sohn, MS Cho, PJ Chung |
Therapeutic Drug Monitoring | 1999 |
5-Fluorouracil Pharmacokinetics: Causes for Variability and Strategies for Modulation in Cancer Chemotherapy
L lyer, MJ Ratain |
Cancer Investigation | 1999 |
Prolonged Severe 5-Fluorouracil-Associated Neurotoxicity in a Patient with Dihydropyrimidine Dehydrogenase Deficiency
N Shehata, A Pater, SC Tang |
Cancer Investigation | 1999 |
Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer—status of the art
E Gamelin, M Boisdron-Celle |
Critical Reviews in Oncology/Hematology | 1999 |
Automated determination of 5-fluorouracil and its metabolite in urine by high-performance liquid chromatography with column switching
T Maeda, S Sumi, K Hayashi, K Kidouchi, T Owaki, H Togari, S Fujimoto, Y Wada |
Journal of Chromatography B Biomedical Sciences and Applications | 1999 |
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
G Milano, MC Etienne, V Pierrefite, M Barberi-Heyob, R Deporte-Fety, N Renée |
British Journal of Cancer | 1999 |
Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage
E Gamelin, M Boisdron-Celle, V Guérin-Meyer, R Delva, A Lortholary, F Genevieve, F Larra, N Ifrah, J Robert |
Journal of Clinical Oncology | 1999 |
Neutropenia following Perioperative Intraperitoneal Chemotherapy
KJ Schnake, PH Sugarbaker, D Yoo |
TUMORI | 1999 |
Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients
AB Kuilenburg, H van Lenthe, MJ Blom, EP Mul, AH Gennip |
British Journal of Cancer | 1999 |
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
WE Evans, MV Relling |
Science | 1999 |
Cardiotoxicity of the Antiproliferative Compound Fluorouracil:
K Becker, JF Erckenbrecht, D Haussinger, T Frieling |
Drugs | 1999 |
Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase
RB Diasio |
British Journal of Clinical Pharmacology | 1998 |
Pharmacogenetics of cancer therapy: getting personal
EY Krynetski, WE Evans |
The American Journal of Human Genetics | 1998 |
Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
SA Ridge, J Sludden, X Wei, A Sapone, O Brown, S Hardy, P Canney, P Fernandez-Salguero, FJ Gonzalez, J Cassidy, HL McLeod |
British Journal of Cancer | 1998 |
Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy
P Canal, E Gamelin, G Vassal, J Robert |
Pathology & Oncology Research | 1998 |
Neurological complications of 5-fluorouracil chemotherapy: Case report and review of the literature
HA Bygrave, JI Geh, Y Jani, R Glynne-Jones |
Clinical Oncology | 1998 |
Pharmacogenetics and cancer chemotherapy
L Iyer, MJ Ratain |
European Journal of Cancer | 1998 |
5-Fluorouracil-related encephalopathy: at least two distinct pathogenetic mechanisms exist - reply
KH Yeh, AL Cheng |
British Journal of Cancer | 1998 |
Purine and Pyrimidine Metabolism in Man IX
A Griesmacher, MM Müller, P Chiba |
1998 | |
High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy
KH Yeh, AL Cheng |
British Journal of Cancer | 1997 |
Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity
AV Kuilenburg |
European Journal of Cancer | 1997 |
Subcellular Localization of Dihydropyrimidine Dehydrogenase
AB van Kuilenburg, HV Lenthe, RJ Wanders, AH van Gennip |
Biological Chemistry | 1997 |
The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster*
J Yan, SK Tyring, MM McCrary, PC Lee, S Haworth, R Raymond, SJ Olsen, RB Diasio |
Clinical Pharmacology & Therapeutics | 1997 |
A Simple Chromatographic Method for the Analysis of Pyrimidines and their Dihydrogenated Metabolites
E Gamelin, M Boisdron-Celle, F Larra, J Robert |
Journal of Liquid Chromatography & Related Technologies | 1997 |
EXPERIMENTAL CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF COLORECTAL CARCINOMA
S O'Reilly, EK Rowinsky |
Hematology/Oncology Clinics of North America | 1997 |
Simultaneous Determination of Dihydrofluorouracil and 5-Fluorouracil in Plasma by High-Performance Liquid Chromatography
SP Ackland, MB Garg, RH Dunstan |
Analytical Biochemistry | 1997 |
Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity
MR Johnson, J Yan, L Shao, N Albin, RB Diasio |
Journal of Chromatography B: Biomedical Sciences and Applications | 1997 |
Common cancers—Immunotherapy and multidisciplinary therapy: Parts III and IV
WD Quan, CS Palackdharry |
Disease-a-Month | 1997 |
Mechanisms of Action and modulation of fluorouracil
JL Grem |
Seminars in radiation oncology | 1997 |
Inborn errors of pyrimidine degradation: Clinical, biochemical and molecular aspects
AH van Gennip, NG Abeling, P Vreken, AB van Kuilenburg |
Journal of Inherited Metabolic Disease | 1997 |
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity
X Wei, HL McLeod, J McMurrough, FJ Gonzalez, P Fernandez-Salguero |
Journal of Clinical Investigation | 1996 |
A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency
P Vreken, AB Kuilenburg, R Meinsma, GP Smit, HD Bakker, RA Abreu, AH Gennip |
Journal of Inherited Metabolic Disease | 1996 |
Individualizing Therapy with 5-Fluorouracil Related to Dihydropyrimidine Dehydrogenase: Theory and Limits
G Milano, MC Etienne |
Therapeutic Drug Monitoring | 1996 |
Preliminary examination of the influence of incubation time or cytosolic protein concentration on dihydropyrimidine dehydrogenase activity
T Tateishi, H Nakura, M Watanabe, M Tanaka, T Kumai, S Kobayashi |
Clinica Chimica Acta | 1996 |
Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole: The use of thallium SPECT imaging to assist in noninvasive diagnosis--A case report
DM Savarese, J Gordon, TW Smith, NS Litofsky, R Licho, R Ragland, L Recht |
Cancer | 1996 |
The activity of dihydropyrimidine dehydrogenase from rat liver was not affected by any of five 5-hydroxytryptamine antagonists
T Tateishi, H Nakura, M Watanabe, M Tanaka, T Kumai, S Kobayashi |
Cancer Letters | 1996 |
Pyrimidines and CNS regulation
GP Connolly, HA Simmonds, JA Dulay |
Trends in Pharmacological Sciences | 1996 |
Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine*
R Peck, R Wiggs, J Callaghan, R Wootton, P Crome, I Fraser, L Frick, J Posner |
Clinical Pharmacology & Therapeutics | 1996 |
cDNA cloning of bovine liver dihydropyrimidine dehydrogenase
N Albin, MR Johnson, RB Diasio |
Mitochondrial DNA | 1996 |
Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta
P Beuzeboc, JY Pierga, D Stoppa-Lyonnet, MC Etienne, G Milano, P Fouillait |
European Journal of Cancer | 1996 |
Monoclonal Antibodies in Cancer Therapy: New Perspectives After the Colorectal Carcinoma Trial
E Holz, R Gruber, G Riethmüller |
Clinical immunotherapeutics | 1996 |
Leading Article: Oncologic, Endocrine & Metabolic: New antimetabolites in preclinical and clinical development
GJ Peters, SP Ackland |
Expert Opinion on Investigational Drugs | 1996 |
A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency
P Vreken, AB Kuilenburg, R Meinsma, GP Smit, HD Bakker, RA Abreu, AH van Gennip |
Journal of Inherited Metabolic Disease | 1996 |
Chronobiology Implications for cancer chemotherapy
GA Bjarnason |
Acta Oncologica | 1995 |
Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes
P Fernandez-Salguero |
Biochemical Pharmacology | 1995 |
Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy*
Z Lu, R Zhang, RB Diasio |
Clinical Pharmacology & Therapeutics | 1995 |
Human Polymorphism in Drug Metabolism: Mutation in the Dihydropyrimidine Dehydrogenase Gene Results in Exon Skipping and Thymine Uracilurea
R Meinsma, P Fernandez-Salguero, AV Kuilenburg, AV Gennip, F Gonzalez |
DNA and Cell Biology | 1995 |
Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities
F Stéphan, MC Etienne, C Wallays, G Milano, F Clergue |
The American Journal of Medicine | 1995 |
Role of the Lung in Accumulation and Metabolism of Xenobiotic Compounds — Implications for Chemically Induced Toxicity
H Foth |
Critical Reviews in Toxicology | 1995 |
Combined deficiencies of NADPH- and NADH-dependent dihydropyrimidine dehydrogenases, a new finding in a family with thymine-uraciluria
AH van Gennip, H van Lenthe, NG Abeling, HD Bakker, AB van Kuilenburg |
Journal of Inherited Metabolic Disease | 1995 |
Concepts, Mechanisms, and New Targets for Chemotherapy
FM Muggia |
1995 | |
Individual dose adaptation of anticancer drugs
B Desoize, J Robert |
European Journal of Cancer | 1994 |
Évolution de la pharmacocinétique à la pharmacogénétique. L'exemple du 5-fluorouracile
G Milano, MC Étienne |
La Revue de Médecine Interne | 1994 |
Purine and Pyrimidine Metabolism in Man VIII
A Sahota, MW Taylor |
1994 | |
Plasma 5-fluorouracil and ?-fluoro-?-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil
L Thiberville, P Compagnon, N Moore, G Bastian, MO Richard, MF Hellot, C Vincent, MM Kannass, S Dominique, C Thuillez, G Nouvet |
Cancer Chemotherapy and Pharmacology | 1994 |
Cancer Treatment An Update
P Banzet, JF Holland, D Khayat, M Weil |
1994 | |
Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2′-deoxyuridine
HJ Keizer, EA Bruijn, UR Tjaden, ED Clercq |
Journal of Cancer Research and Clinical Oncology | 1994 |
cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria
H Yokota, P Fernandez-Salguero, H Furuya, K Lin, OW McBride, B Podschun, KD Schnackerz, FJ Gonzalez |
The Journal of biological chemistry | 1994 |
Pharmacogenetic Phenotyping and Genotyping: Present Status and Future Potential
FJ Gonzalez, JR Idle |
Clinical Pharmacokinetics | 1994 |
5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil
DP Baccanari, ST Davis, VC Knick, T Spector |
Proceedings of the National Academy of Sciences | 1993 |
Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions
R Mick, MJ Ratain |
Cancer Chemotherapy and Pharmacology | 1993 |
The effect of dietary protein depletion on hepatic 5-Fluorouracil metabolism
LE Davis, RE Lenkinski, MA Shinkwin, HY Kressel, JM Daly |
Cancer | 1993 |
Severe 5-Fluorouracil Toxicity in a Patient with Decreased Dihydropyrimidine Dehydrogenase Activity
AP Lyss, RC Lilenbaum, BE Harris, RB Diasio |
Cancer Investigation | 1993 |
Identity of D-3-aminoisobutyrate-pyruvate aminotransferase with alanine-glyoxylate aminotransferase 2
Y Kontani, M Kaneko, M Kikugawa, S Fujimoto, N Tamaki |
Biochimica et Biophysica Acta (BBA) - General Subjects | 1993 |
Dihydropyrimidine dehydrogenase activity in cancer patients
GA Milano, MH Gaspard, A Thyss, N Renée, M Schneider, F Demard, RA Fleming, PJ Bargnoux, R Plagne |
European Journal of Cancer | 1993 |
The Role of Pharmacogenetics in Cancer Chemotherapy and the Development of Malignancy
RJ Irvin, JG Kuhn |
Journal of Pharmacy Practice | 1993 |
Acid-base catalytic mechanism of dihydropyrimidinase from pH studies
K Jahnke, B Podschun, KD Schnackerz, J Kautz, PF Cook |
Biochemistry | 1993 |
Molecular Genetics, Biochemistry and Clinical Aspects of Inherited Disorders of Purine and Pyrimidine Metabolism
U Gresser |
1993 | |
Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients
GA Bjarnason, IG Kerr, N Doyle, M Macdonald, M Sone |
Cancer Chemotherapy and Pharmacology | 1993 |
Purification and characterization of dihydropyrimidine dehydrogenase from human liver
ZH Lu, R Zhang, RB Diasio |
The Journal of biological chemistry | 1992 |
Dihydropyrimidinuria: a new inborn error of pyrimidine metabolism
M Duran, P Rovers, PK Bree, CH Schreuder, H Beukenhorst, L Dorland, R Berger |
Journal of Inherited Metabolic Disease | 1991 |
The Multifrequency (Circadian, Fertility Cycle, and Season) Balance between Host and Cancer
WJ Hrushesky |
Annals of the New York Academy of Sciences | 1991 |
Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome
BE Harris, JT Carpenter, RB Diasio |
Cancer | 1991 |
Oxidation of 5-Bromo- and 5-Fluoro-1,3-dimethyluracils by Peroxomono- and Peroxodisulfate Ions
T Itahara, A Nishino |
Chemistry Letters | 1991 |
Biochemical Basis for Circadian-Dependent Metabolism of Fluoropyrimidines
GC Daher, BE Harris, EM Willard, RB Diasio |
Annals of the New York Academy of Sciences | 1991 |
Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil
GC Daher, FN Naguib, MH el Kouni, R Zhano, SJ Soong, RB Diasio |
Biochemical Pharmacology | 1991 |
Purine and Pyrimidine Metabolism in Man VII
RA Harkness, GB Elion, N Zöllner |
1991 | |
A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients
C Coustre, F Mentr, JP Sommadossi, RB Diasio, JL Steimer |
Cancer Chemotherapy and Pharmacology | 1991 |
Inactivation of dihydropyrimidine dehydrogenase by 5-iodouracil
DJ Porter, WG Chestnut, LC Taylor, BM Merrill, T Spector |
The Journal of biological chemistry | 1991 |
Dihydropyrimidinuria: a new inborn error of pyrimidine metabolism
M Duran, P Rovers, PK de Bree, CH Schreuder, H Beukenhorst, L Dorland, R Berger |
Journal of Inherited Metabolic Disease | 1991 |
Metabolism of pyrimidine analogues and their nucleosides
GC Daher, BE Harris, RB Diasio |
Pharmacology & Therapeutics | 1990 |
A new case of dihydropyrimidine dehydrogenase deficiency
M Brockstedt, C Jakobs, LM Smit, AH Gennip, R Berger |
Journal of Inherited Metabolic Disease | 1990 |
5-Fluorouracil neurotoxicity
DH Moore, WC Fowler, LS Crumpler |
Gynecologic Oncology | 1990 |
Dihydropyrimidinuria
M Duran, P Rovers, PK Bree, CH Schreuder, H Beukenhorst, L Dorland, R Berger |
The Lancet | 1990 |
Neurological Adverse Reactions to Anticancer Drugs
J Hildebrand |
1990 | |
A new case of dihydropyrimidine dehydrogenase deficiency
M Brockstedt, C Jakobs, LM Smit, AH van Gennip, R Berger |
Journal of Inherited Metabolic Disease | 1990 |
Purification and properties of 5,6-dihydropyrimidine amidohydrolase from calf liver
J KAUTZ, KD SCHNACKERZ |
European Journal of Biochemistry | 1989 |
Clinical Pharmacology of 5-Fluorouracil:
RB Diasio, BE Harris |
Clinical Pharmacokinetics | 1989 |
Circadian rhythm of rat liver dihydropyrimidine dehydrogenase
BE Harris, R Song, YJ He, SJ Soong, RB Diasio |
Biochemical Pharmacology | 1988 |
Pharmacogenetics
BM Watson |
Anaesthesia | 1969 |